SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Kubota Y, Hosaka M, Fukushima S. Prophylactic oral UFT therapy for superficial bladder cancer. Cancer. 1993; 71: 18421845.
  • 2
    Ueda T, Iguchi A, Sagiyama K, Kyushu University Urological Oncology Group. Early intravesical instillation of Adriamycin with oral administration of 5-fluorouracil after transurethral resection for superficial bladder cancer: Preliminary results. Cancer Chemother Pharmacol. 1987; 20: 841843.
  • 3
    Pinedo HM, Peters GJ. 5-Fluorouracil: biochemistry and pharmacology. J Clin Oncol. 1988; 6: 1653s1664.
  • 4
    Santi DV, McHenry CS, Sommer H. Mechanisms of interaction of thymidylate synthase with 5-fluorodeoxyuridine. Biochemistry. 1974; 13: 471480.
  • 5
    Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993; 53: 40044009.
  • 6
    Inaba M, Mitsuhashi J, Sawada H, et al. Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res. 1996; 87: 212220.
  • 7
    Kanai F, Kawakami T, Hamada H, et al. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res. 1998; 58: 19461951.
  • 8
    Inaba M, Sawada H, Sadata A, Omata M. Circumvention of 5-fluorouracil resistance in human stomach cancer cells by uracil phosphoribosyltransferase gene transduction. Jpn J Cancer Res. 1999; 90: 349354.
  • 9
    Mizutani Y, Wada H, Ogawa O, et al. Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer. 2001; 92: 510518.
  • 10
    Mizutani Y, Wada H, Yoshida O, et al. Significance of thymidylate synthase activity in renal cell carcinoma. Clin Cancer Res. 2003; 9: 14531460.
  • 11
    Mizutani Y, Wada H, Yoshida O, Fukushima M, Kamoi K, Miki T. Prognostic significance of thymidine kinase activity in bladder cancer. Cancer. 2002; 95: 21202125.
  • 12
    Mizutani Y, Wada H, Yoshida O, Fukushima M, Nakao M, Miki T. Significance of thymidine kinase activity in renal cell carcinoma. J Urol. 2003; 169: 706709.
  • 13
    Wu XX, Mizutani Y, Kakehi Y, Yoshida O, Ogawa O. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by Adriamycin. Cancer Res. 2000; 60: 29122918.
  • 14
    Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y, Yoshida O. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin-6 monoclonal antibody or anti-interleukin-6-receptor monoclonal antibody. Cancer Res. 1995; 55: 590596.
  • 15
    Mizutani Y, Nakanishi H, Yoshida O, Fukushima M, Bonavida B, Miki T. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer. 2002; 38: 167176.
  • 16
    Mizutani Y, Wada H, Yoshida O, et al. Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma. Eur J Cancer. 2003; 39: 541547.
  • 17
    Danenberg PV. Thymidylate synthase: a target enzyme in cancer chemotherapy. Biochem Biophys Acta. 1977; 473: 7392.
  • 18
    Navalgund LG, Rossano C, Muench AJ. Cell cycle regulation of thymidylate synthase gene expression in cultured mouse fibroblasts. J Biol Chem. 1980; 255: 73867390.
  • 19
    O'Neil KL, Grigsby RV, Fairbairn DW. Thymidine kinase: the future in breast cancer prognosis. Breast. 1995; 4: 7983.
  • 20
    Foekens JA, Romain S, Look MP, Martin PM, Klijn JGM. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. Cancer Res. 2001; 61: 14211425.
  • 21
    Ikenaka K, Fukushima M, Nakamura H, Okamoto M, Shirasaka T, Fujii S. Metabolism of pyrimidine nucleotides in various tissues and tumor cells from rodents. Jpn J Cancer Res. 1981; 72: 590597.
  • 22
    Lamm DL, van der Meijden APM, Mizutani Y, et al. Intravesical chemotherapy and immunotherapy: How do we assess their effectiveness and what are their limitations and uses? Int J Urol. 1995; 2: 2335.
  • 23
    Heney, NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer. Progression and recurrence. J Urol. 1983; 130: 10831088.
  • 24
    Pestalozzi BC, Peterson HF, Gelber RD, et al. Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol. 1997; 15: 19231931.
  • 25
    Diasio RB, Lu Z. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol. 1994; 12: 22392242.
  • 26
    Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987; 47: 22032206.
  • 27
    Mizutani Y, Wada H, Fukushima M, et al. Significance of dihydropyrimidine dehydrogenase activity in bladder cancer. Eur J Cancer. 2001; 37: 569575.
  • 28
    Fujii R, Seshimo A, Kameoka S. Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol. 2003; 8: 7278.
  • 29
    Isshi K, Sakuyama T, Gen T, et al. Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU. Int J Clin Oncol. 2002; 7: 335342.